Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Equity Ratio (2020 - 2025)

Maravai Lifesciences Holdings has reported Equity Ratio over the past 6 years, most recently at 0.48 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.48 for Q4 2025, down 15.51% from a year ago — trailing twelve months through Dec 2025 was 0.48 (down 15.51% YoY), and the annual figure for FY2025 was 0.48, down 15.51%.
  • Equity Ratio for Q4 2025 was 0.48 at Maravai Lifesciences Holdings, up from 0.29 in the prior quarter.
  • Over the last five years, Equity Ratio for MRVI hit a ceiling of 0.57 in Q4 2024 and a floor of 0.16 in Q1 2021.
  • Median Equity Ratio over the past 5 years was 0.39 (2023), compared with a mean of 0.39.
  • Biggest five-year swings in Equity Ratio: surged 133.45% in 2021 and later tumbled 41.79% in 2025.
  • Maravai Lifesciences Holdings' Equity Ratio stood at 0.28 in 2021, then skyrocketed by 39.51% to 0.4 in 2022, then surged by 33.88% to 0.53 in 2023, then increased by 7.81% to 0.57 in 2024, then fell by 15.51% to 0.48 in 2025.
  • The last three reported values for Equity Ratio were 0.48 (Q4 2025), 0.29 (Q3 2025), and 0.52 (Q2 2025) per Business Quant data.